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http://dx.doi.org/10.1016/j.jmii.2012Background/Purpose: Dengue cases, traditionally classified as dengue fever (DF) or dengue
hemorrhagic fever (DHF) by the World Health Organization (WHO) dengue classification
1997 scheme, are categorized into Group A (without warning signs), Group B [with warning
signs (e.g., abdominal pain/vomiting/fluid accumulation/mucosal bleeding/lethargy/liver
enlargement/increasing hematocrit with decreasing platelets)], or Group C (severe plasma
leakage/severe bleeding/organ failure) by the WHO 2009 version. We compared differences
in clinical/laboratory features between patients separately classified as DF/DHF and in
Group A/B/C.
Methods: We performed a retrospective analysis of dengue patients diagnosed between 2008
and 2010.
Results: A total of 148 adult patients (119 DF/29 DHF; 64 Group A/77 Group B/7 Group C)
were included. Compared with DF, significantly younger age, lower hospitalization rate,
and higher platelet count were found in Group A. Compared with DHF, higher platelet count
was found in Group B. Six of seven patients (86%) classified as Group C fulfilled the criteria of
DHF. A cross tabulation showed DF cases were distributed in all of the severity groups strat-
ified by the WHO dengue 2009 scheme (53.8% Group A/45.4% Group B/0.8% Group C); of the
DHF cases, 23 (79%) were categorized as Group B, and six (20.7%) as Group C. All patients in
Group A fell into the category DF.nfectious Diseases, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, 123,
iung 833, Taiwan.
.org.tw, drjwliu@yahoo.com.tw (J.-W. Liu).
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272 C.-Y. Tsai et al.Conclusion: The WHO 2009 scheme is effective in identifying severe dengue cases. Heteroge-
neity in severity suggests careful severity discrimination in patients classified in Group B is
needed. Our data suggest that it is safe to treat patients classified as Group A on an outpa-
tient basis.
Copyright ª 2012, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All
rights reserved.Introduction
Dengue is the most prevalent mosquito-borne viral infec-
tion and a major public health problem in the world, with
approximately 2.5 billion people living in dengue endemic
areas worldwide, and 50 million dengue infections occur-
ring annually.1e3 The conventional classification of dengue
illness as dengue fever (DF) or dengue hemorrhagic fever
(DHF) put forward by the World health organization (WHO)
in 1975 was based on the results of studies in pediatric
patients conducted at the Children’s Hospital, Bangkok,
Thailand.4 The diagnosis of DHF established in dengue
infection required the fulfillment of all of the following
criteria: fever, hemorrhagia, thrombocytopenia (<100 
109 cells/L) and clinical evidence of plasma leakage
resulting from increased vascular permeability.5 The
severity of DHF was categorized as follows: Grade IZ fever
accompanied by non-specific constitutional symptoms with
the only hemorrhagic manifestation being a positive tour-
niquet test result; Grade II Z spontaneous bleeding is
observed, in addition to the manifestations of Grade I;
Grade III Z circulatory failure manifested by rapid and
weak pulse and narrowing of pulse pressure or hypotension,
with the presence of cold clammy skin; and Grade
IVZ profound shock with undetectable blood pressure and
pulse. Grades III and IV were categorized as dengue shock
syndrome (DSS).5 Over the past decades, dengue has
geographically expanded and increasingly affected adult
populations.1e3,6e10 A wide variety of dengue clinical
manifestations have continuously been unveiled, adding to
the major dengue presentations that were initially
conceived to be mainly confined to fever and hemor-
rhagia.11e13 Of note, It has been increasingly reported that
severe dengue might not fulfill the criteria of DHF/DSS, yet
put affected patients at high risk for mortality.14e19
Numerous reports on critically ill dengue affected
patients who died of causes other than DHF/DSS have urged
for a revision of the convention WHO dengue classification,
so that it could elicit practical warning signs in a timely
fashion and provide appropriate treatment guidelines for
severe dengue.11e13,20e24 For practical reasons, the latest
WHO dengue classification scheme issued in 2009 stratified
dengue-affected patients, based on the clinical manifes-
tations, laboratory parameters and the clinical-service
delivery, into severe dengue and non-severe dengue
cases.1 However, the usefulness of WHO dengue classifica-
tion 2009 scheme has not yet been fully evaluated.1
Taiwanese clinicians are particularly inexperienced with
the WHO 2009 dengue classification and treatment guide-
lines as most of the large dengue epidemics in Taiwanoccurred before 2009.24,25 The aim of this study was to
evaluate the difference in clinical and laboratory features
between patients who were separately classified based on
the WHO classification 1997 and 2009 schemes, and the
implications of these differences will be discussed.Materials and methods
Patients and definitions
Patients with a diagnosis of acute dengue virus (DENV)
infection admitted to Kaohsiung Chang Gung Memorial
Hospital (KSCGMH), a 2700-bed medical facility serving as
a primary and tertiary referral center in southern Taiwan,
between 2008 and 2010 were included for retrospective
analysis. The medical charts of the included patients
were reviewed for retrieval of demographic, clinical,
laboratory and imaging information. All included dengue
cases were confirmed by at least one of the following
criteria: (i) a positive reverse transcriptase-polymerase
chain reaction (RT-PCR) result in acute-phase serum,
(ii) a positive result for specific immunoglobulin M anti-
body in acute-phase serum, (iii) a fourfold increase in
dengue-specific hemagglutination inhibition titer in
convalescent serum as compared with that in acutee
phase, and (iv) a dengue-specific nonstructural glyco-
protein NS1 detected in acute-phase serum.26e28 These
diagnostic tests were performed by the Taiwan Center for
Disease Control (CDC, Taiwan).
All included patients had their blood sampled for the
assay of hemogram upon their arrival at KSCGMH. Addi-
tional blood chemistry and follow-up hemogram tests
during hospital stay were carried out at the discretion of
his or her physician as was clinically indicated. An organ
impairment in the dengue-affected patient referred to
any of the following clinical conditions: pulmonary
edema, respiratory failure, severe gastrointestinal tract
bleeding, severe hepatitis and rhabdomyolysis.1 Severe
hepatitis was defined as an elevated alanine amino-
transferase (ALT) and/or aspartate aminotransferase
(AST) >1000 U/L [normal range (NR), ALT and AST,
<40 U/L],1 rhabdomyolysis are five or more times the
upper limit of normal serum creatine kinase (NR,
20e130 U/L) and/or presence of myoglobin in the blood
and/or urine,29 and severe gastrointestinal bleeding as
the passage of large amount of tarry or bloody stool
coupled with hemodynamic instability and/or rapid
decrease in hemoglobin level.13 Plasma leakage referred
to the presence of pleural effusion, ascites, and/or
Dengue classification schemes 273hemoconcentration. Hemoconcentration referred to
>20% increase in hematocrit calculated as: (maximum
hematocrit e minimum hematocrit)  100%/minimum
hematocrit.1,5,13WHO dengue classification 1997 and 2009 schemes
The definitions and severity stratifications of dengue in the
WHO 1997 and 2009 schemes are summarized in Table 1.1,5
Briefly, the WHO 1997 scheme classified dengue disease
into DF and DHF (Grades IIV)5; the WHO 2009 scheme
classified dengue disease into dengue without warning
signs, dengue with warning signs (i.e., abdominal pain/
tenderness, persistent vomiting, clinical fluid accumula-
tion, mucosal bleed, lethargy, liver enlargement >2 cm,
and increase in hematocrit concurrent with rapid decrease
in platelet count), and severe dengue.1 Furthermore, the
2009 WHO scheme categorized dengue-affected patients
into: (i) Group A Z patients without warnings signs, (ii)
Group B Z patients with  one warning sign, patients with
 one coexisting conditions (i.e., pregnancy, infancy, old
age, obesity, diabetes mellitus, renal failure, and chronic
hemolytic diseases), and/or those with certain social
circumstances (e.g., living alone or living far from
a healthcare facility), and (iii) Group C Z patients with
severe plasma leakage, severe bleeding, and/or organ
impairment.1Data collection and dengue classifications
The medical records of the included patients were
reviewed. The demographics and evolutionary clinical,
laboratory and imaging information of the included
patients were retrieved and recorded in a case report
form. These data were presented at a group discussion
and the classified severity of dengue in individual patients
based on WHO 1997 and 2009 classification schemes were
the consensus of the participating infectious-disease
physicians.Statistical analyses
The included patients were separately classified as (i) DF
or DHF, according to the 1997 WHO case classification, and
(ii) Group A, Group B or Group C, based on the 2009 WHO
case definitions. To evaluate the differences between the
2009 and 1997 WHO classification schemes, univariate
analyses were performed to compare clinical, laboratory
and imaging features of patients between (i) Group A and
DF, (ii) Group B and DF, (iii) Group C and DF, (iv) Group A
and DHF, (v) Group B and DHF, and (vi) Group C and DHF. A
cross tabulation of Group A/B/C and DF/DHF was made.
Student’s t test or Mann-Whitney U test was used for
comparisons between continuous variables, whereas the
Chi-square test or Fisher exact test was used for
comparison between dichotomous variables. A statisti-
cally significant difference was determined by a p value
<0.05.Ethics statement
The study was conducted with a waiver of patient consent
approved by the Institutional Review Board of KSCGMH
(Document No.: 100-3061B).Results
Characteristics of the overall included patients
Of a total of 148 patients (83 men and 65 women; mean
age, 45.2  18.9 years) each involved in one dengue case
included, 41 (27.7%) were diagnosed in 2008, 64 (43.2%) in
2009, and 43 (29.1%) in 2010. The demographic, clinical,
laboratory and imaging information of the included patients
is summarized in Tables 2 and 3. The mean interval from
dengue onset to hospital presentation was 3.7  1.9 days.
The most common underlying condition was hypertension
(20%) and diabetes mellitus (11.3%). The three leading
symptoms were fever (85.8%), myalgia (64.9%) and rashes
(60%). As for warning signs, nausea/vomiting was found in
43 (29.1%) patients, mucosal bleeding (gum bleeding,
hematuria and/or gastrointestinal bleeding) in 33 (22.3%),
abdominal pain in 32 (21.6%), and drowsiness in one (0.7%).
Platelet transfusion was given to 40 (27%) patients. Hemo-
concentration was noted in 16 (10.8%) patients. Pleural
effusion was found in 16 (15.1%) of the 106 patients with
chest X-ray available, and ascites was detected in seven
(8%) of the 87 patients with abdominal sonography avail-
able. Of the overall 64 DENV serotypes identified, DENV-3
accounting for 53.1%, followed by DENV-2 (28.1%), DENV-1
(17.2%) and DENV-4 (1.6%). All of the included patients
survived.Description of the included patients classified by
the WHO 1997 scheme (Tables 2 and 3)
Of the 148 included patients, 119 [80.4%; median age, 45.7
years (range, 7e75)] were classified as suffering DF, and 29
[19.6%; median age, 53.7 years (range, 11e83)] as DHF.
Seventy two (60.5%) of DF patients were hospitalized.
Among the 119 DF patients, hemorrhage (gum bleeding,
gastrointestinal bleeding and/or hematuria) was found in
27 (22.7%), the median platelet count was 56.5  109 cells/
L (range, 3.0e202 cells/L), the median peak hematocrit
level was 42.8% (range, 31.5%e53.7%), platelet transfusion
was given to 25 (21%) patients and rhabdomyolysis was
found in one (0.8%).
Twenty seven (93.1%) of the 29 DHF (19 Grade I and 10
Grade II) patients were hospitalized. Among the 29 DHF
patients, severe gastrointestinal bleeding and rhabdo-
myolysis each was found in two patients (each 6.9%), the
median platelet count was 42.8  109 cells/L (range,
2.0e91), and the median peak hematocrit level was 44.7%
(range, 27.7e58.2). and platelet transfusion was given to
15 (51.7%) patients. Fourteen DHF patients with RT-PCR
data available, and DENV-3 was found to be the etiologic
virus in seven (50%) of them.
Table 1 Severity stratifications of laboratory-confirmed dengue illness by the 1997 and 2009 World Health Organization (WHO) dengue classification schemes
1997 WHO classification schemes 2009 WHO classification schemes
Dengue fever Dengue hemorrhagic fevera Dengue without
warning signsb (Group A)
Dengue with warning
signsb (Group B)
Severe dengue (Group C)
Acute illness with  2 of
the following symptoms:
 Fever
 Headache
 Retro-orbital pain
 Myalgia
 Arthralgia
 Rash
 Hemorrhagic
manifestations
All the following:
 Fever
 Hemorrhagia (e.g., positive
tourniquet test, petechiae,
ecchymosis, purpura, and bleeding
from mucosa, gastrointestinal tract,
injection sites or other locations)
 Thrombocytopenia (platelet
count <100 000 cells/mL);
 Evidence of plasma leakage due
to increased vascular permeability
(e.g., hemoconcentration,
pleural effusion, ascites and/or
hypo-proteinemia)
Patients who do not have
warning signsb AND
who are able:
 to tolerate adequate
volumes of oral fluid
replacement
 to pass urine at least
once every 6 hours
Patients with any of
following features:
 Co-existing conditions such as
pregnancy, infancy, old age,
diabetes mellitus, and renal failure
 Social circumstances such as living
alone, living far from hospital
 Existing warning signb
Patients with any of the
following features:
 Severe plasma leakage
with shock and/or fluid
accumulation leading to
respiratory distress
 Severe bleeding
 Severe organ impairmentc
a Dengue hemorrhagic fever were categorized into grades IIV (see text for details).
b Warning signs: abdominal pain or tenderness, persistent vomiting; clinical fluid accumulation, mucosal bleeding, lethargy, restlessness, liver enlargement >2 cm, increase in
hematocrit concurrent with rapid decrease in platelet count.
c Severe organ impairment: severe hepatitis was defined as an elevated alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) >1000 U/L (normal range [NR], ALT and
AST, <40 U/L),1 rhabdomyolysis as 5 times the upper limit of normal serum creatine kinase (NR, 20e130 U/L) and/or presence of myoglobin in the blood and/or urine.29
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Table 2 Demographic and clinical features of the included patients according to 1997 and 2009 World Health Organization (WHO) dengue schemes
Variable Total cases
(N Z 148)
1997 WHO classification 2009 WHO classification p
(Gr A vs. DF)
p
(Gr B vs. DF)
p
(Gr C vs. DF)
p
(Gr A vs. DHF)
p
(Gr B vs. DHF)
p
(Gr C vs. DHF)
p
(Gr C vs. DHF)
(n Z 119)
DHF
(n Z 29)
Group A
(n Z 64)
Group B
(n Z 77)
Group C
(n Z 7)
Demographic and
clinical features
Age (yr) 0.007 0.004 NS 0.001 NS NS
Mean 45.2  18.9 43.8  18.8 50.7  19 36.1  17.6 51.8  16.8 55.4  19.8
Median (range) 48.3 (7e83) 45.7 (7e75) 53.7 (11e83) 34.5 (7e64) 56.2 (11e77) 60 (28e83)
Male, n (%) 83 (56.1) 66 (55.5) 17 (58.6) 30(46.9) 48 (62.3) 5 (71.4) NS NS NS NS NS NS
Diabetes mellitus,
n (%)
17 (11.5) 9 (7.9) 8 (27.6) 0 (0) 16 (20.8) 1 (14.3) 0.028 0.009 NS <0.001 NS NS
Hypertension, n (%) 30 (20.3) 18 (15.1) 12 (41.4) 4 (6.3) 22 (28.6) 4 (57.1) NS 0.029 0.018 <0.001 NS NS
Mean day
presented to
hospital after
onset of symptoms
3.7  1.9 3.7  1.9 3.8  1.9 3.8  1.7 3.6  1.9 4.4  2.2 NS NS NS NS NS NS
Hospital
admission, n (%)
99 (66.9) 72 (60.5) 27 (93.1) 28 (43.7) 64 (83.1) 7 (100) 0.043 0.001 0.045 <0.001 NS NS
Dengue fever
with bleeding, n (%)
27 (18.2) 27 (22.7) d d d d d d d d d d
DHF grade I, n (%) 19 (12.8) d 19 (65.5) d d d d d d d d d
DHF grade II, n (%) 10 (6.8) d 10 (34.5) d d d d d d d d d
DENV-1, n/N (%) 11/64 (17.2) 9/50 (18) 2/14 (14.3) 2/23 (8.7) 9/37 (24.3) 0/4 (0) NS NS NS NS NS NS
DENV-2, n/N (%) 18/64 (28.1) 13/50 (26) 5/14 (35.7) 5/23 (21.7) 11/37 (29.7) 1/4 (25) NS NS NS NS NS NS
DENV-3, n/N (%) 34/64 (53.1) 27/50 (54) 7/14 (50) 16/23 (69.6) 16/37 (43.2) 3/4 (75) NS NS NS NS NS NS
DENV-4, n/N (%) 1/64 (1.6) 1/50 (2) 0/14 (0) 0/23 (0) 1/37 (2.7) 0/4 (0) NS NS NS d NS d
Platelet
transfusion, n (%)
40 (27) 25 (21) 15 (51.7) 6 (9.4) 30 (39) 4 (57) NS 0.009 0.049 <0.001 NS NS
Pleural effusion,
n/N (%)
16/106 (15.1) 0/78 (0) 16/28 (57.1) 0/33 (0) 12/66 (18.2) 4/7 (57.1) d <0.001 <0.001 <0.001 NS NS
Ascites, n/N (%) 7/87 (8) 0/62 (0) 7/25 (28) 0/22 (0) 7/59 (11.9) 0/6 (0) d 0.005 d 0.010 NS NS
Gallbladder
swelling, n/N (%)
14/87 (16.1) 9/62 (14.5) 5/25 (20) 2/22 (9.1) 10/59 (16.9) 2/6 (33.3) NS NS NS NS NS NS
Hepatomegaly,
n/N (%)
2/87 (2.3) 0/62 (0) 2/25 (8.0) 0/22 (0) 2/59 (3.4) 0/6 (0) d NS d NS NS NS
Splenomegaly,
n/N (%)
13/87 (14.9) 9/62 (14.5) 4/25 (16) 4/22 (18.2) 8/59 (13.6) 1/6 (16.7) NS NS NS NS NS NS
Severe hepatitis,
n (%)
2 (1.4) 0 2 (6.9) 0 0 2 (28.6) d d 0.003 NS NS NS
Severe
gastrointestinal
bleeding, n (%)
2 (1.4) 0 2 (6.9) 0 0 2 (28.6) d d 0.003 NS NS NS
Rhabdomyolysis,
n (%)
3 (2) 1 (0.8) 2 (6.9) 0 0 3 (42.8) NS NS <0.001 NS NS 0.040
(continued on next page)
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Table 2 (continued )
Variable Total cases
(N Z 148)
1997 WHO classification 2009 WHO classification p
(Gr A vs. DF)
p
(Gr B vs. DF)
p
(Gr C vs. DF)
p
(Gr A vs. DHF)
p
(Gr B vs. DHF)
p
(Gr C vs. DHF)
p
(Gr C vs. DHF)
(n Z 119)
DHF
(n Z 29)
Group A
(n Z 64)
Group B
(n Z 77)
Group C
(n Z 7)
Acute
pulmonary edema,
n (%)
1 (0.7) 0 1 (3.4) 0 0 1 (14.3) d d NS NS NS NS
Symptom/sign,a n (%)
Fever 127 (85.8) 100 (84) 27 (93.1) 52 (81.3) 68(88.3) 7 (100) NS NS NS NS NS NS
Abdominal pain 32 (21.6) 22 (18.5) 10 (34.5) 0 (0) 31 (40.3) 1 (14.3) <0.001 0.001 NS NS NS NS
Retro-orbital pain 18 (12) 15 (12.6) 3 (10.3) 6 (9.3) 11 (14.3) 1 (14.3) NS NS NS NS NS NS
Bone pain 75 (50.7) 56 (49.6) 16 (55.2) 26 (40.6) 44 (57.1) 5 (71.4) NS NS NS NS NS NS
Myalgia 96 (64.9) 76 (63.9) 20 (69) 35 (54.7) 56 (72.7) 5 (71.4) NS NS NS NS NS NS
Cough 39 (26.4) 29 (24.4) 10 (34.5) 11 (17.2) 26 (33.8) 2 (28.6) NS NS NS NS NS NS
Headache 63 (42.6) 52 (43.7) 11 (37.9) 26 (40.6) 33 (42.9) 4 (57.1) NS NS NS NS NS NS
Rashes 88 (59.5) 71 (59.7) 17 (58.6) 37 (57.8) 47 (61) 4 (57.1) NS NS NS NS NS NS
Vomiting/nausea 43 (29.1) 32 (26.9) 11 (37.9) 12 (18.8) 27 (35.1) 4 (57.1) NS NS NS NS NS NS
Diarrhea 16 (10.8) 11 (9.2) 5 (17.2) 6 (9.4) 9 (11.7) 1 (14.3) NS NS NS NS NS NS
Drowsiness 1 (0.7) 0 1 (3.4) 0 0 1 (14.3) d d NS NS NS NS
Gum bleeding 13 (8.8) 10 (8.5) 3 (10.3) 0 (0) 12 (15.6) 1 (14.3) 0.016 NS NS 0.028 NS NS
Petechiae 61 (41.2) 46 (38.7) 15 (51.7) 24 (37.5) 33 (42.9) 4 (57.1) NS NS NS NS NS NS
Gastrointestinal
bleeding
15 (10.1) 10 (8.5) 5(17.2) 0(0) 12 (15.6) 3 (42.9) 0.016 NS 0.024 0.002 NS NS
Hematuria 7 (4.7) 6 (5) 1 (3.4) 0 (0) 6 (7.8) 1 (14.3) NS NS NS NS NS NS
DF Z dengue fever; DHF Z dengue hemorrhagic fever; Gr Z Group; NS Z not significant; n/N Z no. of patients/no. of patients with data available.
a An individual patient might have more than one underlying disease/condition.
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Table 3 Laboratory characteristics of the included patients according to 1997 and 2009 World Health Organization (WHO) dengue schemes
Variable Total cases
(N Z 148)
1997 WHO classification 2009 WHO classification p
(Gr A vs. DF)
p
(Gr B vs. DF)
p
(Gr C vs. DF)
p
(Gr A vs. DHF)
p
(Gr B vs. DHF)
p
(Gr C vs. DHF)
DF
(n Z 119)
DHF
(n Z 29)
Group A
(n Z 64)
Group B
(n Z 77)
Group C
(n Z 7)
Leukopenia
(WBC < 3.0  109
cells/L), n/N (%)
82/146
(56.2)
64/117
(54.7)
18/29
(62.1)
33/62
(53.2)
45/77
(58.4)
4/7
(57.1)
NS NS NS NS NS NS
Leukocytosis
(WBC > 12.0  109
cells/L), n/N (%)
2/146
(1.4)
0/117 (0) 2/29
(6.9)
0/62 (0) 1/77
(1.3)
1/7
(14.3)
d NS NS NS NS NS
Median platelet
count (range)
(109 cells/L)
41
(2.0e202)
56.5
(3.0e202)
21
(2e91)
91.5
(3e202)
35
(2e186)
21
(6e38)
0.024 0.009 0.006 <0.001 0.006 NS
Median peak
hematocrit
(range) (%)
43.3
(27.7e58.2)
42.8
(34.5e53.7)
44.7
(27.7e58.2)
42.3
(35.4e53.4)
43.6
(34.5e58.2)
43.4
(27.7e53.7)
NS NS NS 0.013 NS NS
ALT > 40 U/L
(normal value
< 40 U/L),
n/N (%)
84/131
(64.1)
61/103
(59.2)
23/28 (82.1) 25/52 (48.1) 52/72 (72.2) 7/7 (100) NS NS 0.043 0.004 NS NS
AST > 40 U/L
(normal value
< 40 U/L),
n/N (%)
97/122
(79.5)
70/94 (74.5) 27/28 (96.4) 31/49 (63.3) 59/66 (89.4) 7/7 (100) NS 0.025 NS 0.001 NS NS
Hypoalbuminemia
(<3.0 mg/dl )
(normal range
4.5e3.0 mg/dl),
n/N (%)
3/53 (5.7) 2/41 (4.9) 1/12 (8.3) 0/45 (0) 1/30 (3.3) 2/4 (50) NS NS 0.034 NS NS NS
ALT Z serum alanine aminotransferase; AST Z aspartate aminotransferase; DF Z dengue fever; DHF Z dengue hemorrhagic fever; Gr Z group; NS Z not significant; n/N Z no. of
patients/no. of patients with data available; WBC Z white blood cell.
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278 C.-Y. Tsai et al.Description of the included patients classified by
the WHO 2009 scheme (Tables 2 and 3)
Of 148 included patients, 64 [43.2%; median age, 34.5 years
(range, 7e64)] were allocated to Group A, 77 [52%; median
age, 56.2 years (range, 1e77)] to Group B, and seven [4.7%;
median age, 60 years (range, 28e83)] to Group C.
Among the 64 patients [28 (43.7%) of the patients were
hospitalized] in Group A, the three most common
symptoms/sign were fever (81.3%), rashes (57.8%) and
myalgia (54.7%), the median platelet count was
91.5  109 cells/L (range, 3 to 202), and the median peak
hematocrit level was 42.3% (range, 35.4e53.4); platelet
transfusion was given to six (9.4%) patients.
Among the 77 [64 (83.1%) of the patients were hospi-
talized] patients in Group B, the three leading symptoms
were fever (88.3%), myalgia (72.7%) and bone pain (57.1%);
gastrointestinal bleeding developed in 12 (15.6%), the
median platelet count was 35  109 cells/L (range, 2e186),
and the median peak hematocrit level was 43.6% (range,
34.5e58.2); platelet transfusion was given to 30 (39%)
patients.
All the seven patients in Group C were admitted to
hospital, and the three leading symptoms were fever
(100%), bone pain, and myalgia (each 71.4%). The median
platelet count was 21  109 cells/L (range, 6e38), and the
median peak hematocrit level was 43.4% (range,
27.7e53.7); platelet transfusion was given to four (57%)
patients. The detailed demographics, clinical and labora-
tory features of the patients in Group C are summarized in
Table 4. Of the seven patients allocated in Group C, six
(85.7%) patients were classified as suffering DHF Grade II
(Patients 1, 2 and 4e7), and one as DF (Patient 3). Rhab-
domyolysis was found in three patients (Patients 3, 6 and
7); severe hepatitis (Patients 1 and 6), severe gastrointes-
tinal bleeding (Patients 2 and 6), and respiratory distress
(Patients 4 and 5) each were found in two patients. Of the
two patients experienced respiratory distress, pulmonary
edema was noted in Patient 5, and persistent drowsiness
with respiratory failure that necessitated mechanical
ventilatory support was found in Patient 4. Ventilator
associated pneumonia subsequently developed in Patient 4,
and meropenem was thereby intravenously administrated.
Of the three (Patients 3, 6, and 7) patients complicated
with rhabdomyolysis, concurrent severe hepatitis and
severe gastrointestinal bleeding were found in Patient 6. Of
note, all of the three patients with rhabdomyolysis pre-
senting with myalgia and weakness of both lower limbs.
Tea-colored urine was overt in Patient 3; however, no
evidence of plasma leakage was detected by chest radiog-
raphy and frequent measurement of his hematocrit. DENV-3
was detected in three (75%) of the four patients in Group C
with RT-PCR data available.
Clinical, laboratory and imaging features between
dengue classified by WHO 2009 scheme and DF
(Tables 2 and 3)
Group A vs. DF
Patients in Group A were significantly younger (36.1  17.9
years vs. 43.8  18.8 years; p Z 0.007); had lower
Table 5 Cross tabulation showing ratios of dengue severity in patients (N = 148) separately classified based on the 1997 and
the 2009 World Health Organization (WHO) dengue classification schemes
1997 WHO Classification 2009 WHO Classification Subtotal
Group A Group B Group C
DF 64 54 1 119
W/Xa (%) 64/119 (53.8) 54/119 (45.4) 1/119 (0.8)
Y/Zb (%) 64/64 (100) 54/77 (70) 1/7 (14)
DHF 0 23 6 29
W/Xa (%) 0 23/29 (79.3) 6/29 (20.7)
Y/Zb (%) 0 23/77 (30) 6/7 (86)
Subtotal 64 77 7 Total Z 148
Data are number of patients, unless otherwise indicated.
DF Z dengue fever; DHF Z dengue hemorrhagic fever.
a W/X Z the patient number of Group A or B or C/the subtotal patient number of DF or DHF.
b Y/Z Z the patient number of DF or DHF/the subtotal patient number of Group A or B or C.
Dengue classification schemes 279prevalence of diabetes mellitus (0 vs. 7.9%; p Z 0.028),
lower frequencies of abdominal pain (0 vs.18.5 %;
p < 0.001), gum bleeding (0 vs. 8.5%; p Z 0.015), and
gastrointestinal bleeding (0 vs. 8.4%; p Z 0.016); lower
hospital admission rate (43.7 vs. 60.2%; p Z 0.043), and
higher platelet count (median, 91.5  109 cells/L vs.
56.5  109 cells/L; p Z 0.024).
Group B vs. DF
Patients in Group B were significantly older (51.8  16.8
years vs. 43.8  18.8 years; p Z 0 .004); had higher prev-
alences of diabetes mellitus (20.8% vs. 7.9%; pZ 0.009) and
hypertension (28.6% vs. 15.1%; p Z 0.029), higher inci-
dences of pleural effusion (18.2% vs. 0; p < 0.001), ascites
(11.9% vs. 0; p Z 0005), and abdominal pain (40.3% vs.
18.5%; pZ 0.001); higher hospital admission rate (83.1% vs.
60.2%; p Z 0.001), lower platelet count (median,
35  109 cells/L vs. 56.5  109 cells/L; p Z 0.009), higher
serum AST level (89.4% vs. 74.5%; p Z 0.025), and higher
proportion of receiving platelet transfusion (39% vs. 21%;
p Z 0.009).
Group C vs. DF
Patients in Group C were significantly had higher prevalence
of hypertension (57.1% vs. 15.1%; pZ 0.018), higher hospital
admission rate (100% vs. 60.2%; p Z 0.045), higher inci-
dences of severe hepatitis (28.6% vs. 0; p Z 0.003), rhab-
domyolysis (42.8% vs. 0.8%; p < 0.001), gastrointestinal
bleeding (42.9% vs. 8.4%; pZ 0.024), severe gastrointestinal
bleeding (28.6% vs. 0; pZ 0.003), pleural effusion (57.1% vs.
0; p < 0.001); and hypoalbuminemia (50% vs. 4.9%; p =
0.034), lower platelet count (median, 21  109 cells/L vs.
56.2  109 cells/L; p Z 0.006), higher serum ALT (100% vs.
59.2%; pZ 0.043) levels, and higher proportion of receiving
platelet transfusion (57% vs. 21%; pZ 0.049).
Clinical, laboratory and imaging features between
dengue classified by WHO 2009 scheme and DHF
(Tables 2 and 3)
Group A vs. DHF
Patients in Group A were significantly younger (mean,
36.1  17.6 years vs. 50.7  19 years; p Z 0,001); hadlower prevalences of diabetes mellitus (0 vs. 27.6%;
p < 0.001) and hypertension (6.3% vs. 41.4%; p < 0.001);
lower hospital admission rate (43.7 vs. 93.1%; p < 0.001),
higher platelet count (91.5  109 cells/L vs. 21  109 cells/
L; p < 0.001), lower peak hematocrit (median, 42.3% vs.
44.7%; pZ 0.013), and lower incidences of gastrointestinal
bleeding (0 vs. 17.2%; pZ 0.002), gum bleeding (0 vs. 28%;
p Z 0.010), pleural effusion (0 vs. 57.1 %; p < 0.001) and
ascites (0 vs. 28%; pZ 0.010); lower proportion of receiving
platelet transfusion (9.4% vs. 51.7%; p < 0.001).
Group B vs. DHF
Patients in Group B had significantly higher platelet count
(median, 35  109 cells/L vs. 21  109 cells/L; p Z 0.006).
Group C vs. DHF
Patients in Group C were had significantly higher incidence
of rhabdomyolysis (42.8% vs. 6.9%; p Z 0.040).
Cross tabulation of dengue Group A/B/C and DF/
DHF (Table 5)
Cases of DF were distributed in all of the severity groups
stratified based on the WHO dengue 2009 scheme; of the
119 DF cases, 64 (53.8%) were categorized as Group A, 54
(45.4%) as Group B, one (0.8%) as Group C. Cases of DHF
were distributed in either Group B or Group C; of the 29
DHF cases, 23 (79.3%) were categorized as Group B, and six
(20.7%) as Group C. Contrariwise, all of the 64 patients
allocated in Group A were categorized as DF; 70% (54/77
patients) and 30% (23/77 patients) of Group B were cate-
gorized as DF and DHF, respectively; and 14% (1/7 patients)
and 86% (6/7 patients) of Group C were categorized as DF
and DHF, respectively.
Discussion
Clinical severity in dengue illness steps up from DF to DHF,
as stratified based on the WHO dengue classification 1997
scheme,5 and from Group A, Group B to Group C, as strat-
ified based on its 2009 version.1 Substantial significant
differences in demographic, laboratory and clinical vari-
ables between Group A/B/C and DF/DHF shown in Results
280 C.-Y. Tsai et al.suggest that stratifications based on the WHO dengue 2009
and 1997 schemes are not interchangeable in terms of
evaluation of clinical severity of dengue illness. The
advantages of applying the WHO dengue classification 2009
scheme are that what clinicians need at treating dengue
are to keep vigilant eye on the emergence of clinically
easily recognizable warning signs and severe dengue, and
manage patients according to the established guidelines.1
Our data show that if reclassified based on WHO dengue
classification 2009 scheme, 53.8%, 45.4%, and 0.8% of DF
cases fell into Group A, Group B, and Group C, respectively,
while 79.3% and 20.7% DHF cases fell into Group B and
Group C, respectively. These data suggest that only 53.8%
of DF patients in the present series be considered appro-
priate for treatment on outpatient basis,30 while another
46.2% of DF patients and all DHF patients probably or
absolutely need hospitalization for strict observations and/
or aggressive intervention.1 Our data implicate the a great
heterogeneity of DF in terms of clinical severity, and
different levels of clinical severity of DF are discriminated
by the WHO dengue classification 2009 scheme.
By contrast, 100% of the patients allocated in Group A
in the current series were categorized as DF, and
approximately 30% of Group B and 86% of Group C were
categorized as DHF. These data suggest that when strati-
fied by WHO dengue classification 2009 scheme, dengue
patients classified in Group A should be treated on
outpatient basis, and escalating proportions of dengue
patients categorized from Group B to Group C need
admission for close observation and/or intervention as
necessary. Of note, the hospitalization rates in this series
were found to be 60.5% in DF patients, 93.1% in DHF
patients, and 43.7%, 83.1%, and 100% in patients in Group
A, Group B, and Group C, respectively. In consistent with
previous report, 31 our data suggest that the WHO 2009
scheme better discriminate different levels of clinical
severity among dengue-affected patients.
In comparison to its 1997 version, the WHO dengue
classification 2009 scheme were also reported to have
a higher sensitivity and specificity in identifying dengue
cases that clinically progress requiring intensive care.31 As
dengue features clinically dynamic change over time,13,31
when being treated on outpatient basis for whatever
reasons, the dengue-affected patient categorized in Group
A or Group B and the family should be notified to pay
careful attention to the potential emergence of any newly
developing warning sign and/or exacerbation of the pre-
existing warning sign(s) that necessitates hospitalization.
In addition to addressing what happens in dengue
patients surrounding the plasma leakage and bleeding as
the WHO 1997 version did, the WHO 2009 scheme include
the warning signs as monitor targets and severe organ
impairment as part of the criteria in severe dengue,1
comprehensively depicting what happens in reality. For
instance, clinical manifestations of dengue patients cate-
gorized in Group C in this series (Table 4) were obviously
much better detailed by the WHO 2009 scheme than by its
previous version. This is not surprising as the WHO 2009
version was written to provide practical guidance to deal
with dengue, which often occurs as a large-scale epidemic
in areas where medical resources are deficient. On top of
that, the WHO 2009 scheme takes into account otherfactors such as coexisting conditions (e.g., pregnancy,
infancy, old age, diabetes mellitus, and renal failure) and
social circumstances (e.g., living alone and/or far from
a hospital) when it comes to consideration for dengue
patient hospitalization for close observation.1
During the 3-year-study period, there were more than
3000 cases of symptomatic dengue cases notified in
Taiwan.32 DENV-1 was circulating in 2008, while DENV-3 was
the predominant serotype between 2009 and 2010 and
DENV-2 was sporadically found in 2010.32 DENV-2 was re-
ported to be more clinically virulent and associated with
severe manifestations in some series.33,34 Of note, Narvaez
et al.31 reported that DENV-2 was significantly associated
with DHF/DSS, suggesting that the WHO dengue 2009
scheme was no longer specific in identifying severe dengue
due to DENV-2. The association of DENV-2 and clinical
severity was not found in our series. Rather, DENV-3 was
found to be the most common serotype detected in
patients with DHF and in those categorized in Group C. The
higher linking between DENV-3 and DHF/severe dengue in
our series partly resulted from the fact that DENV-3 was the
dominant serotype in circulation during the study period.
There are some limitations in our study. First, the study
was conducted at a single medical center, and the dengue
severity of patients may therefore be biased by referral
pattern. Second, the small sub-grouped case numbers make
the statistical power quite small. Third, being a retrospec-
tive study, missing data for some included patients were
unavoidable.
In conclusion, data from this study show that the WHO
2009 scheme is effective in identifying severe dengue
cases. Heterogeneity in severity suggested careful severity
discrimination in patients classified in Group B by clinicians
is needed. Our data suggests that it is safe to treat dengue-
affected patients classified in Group A on outpatient basis.Acknowledgments
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